Get the Daily Brief
Latest Biotech News
Inhibrx posts phase 2 win in rare bone cancer – FDA filing eyed for 2026
Inhibrx reported positive registrational Phase 2 results for ozekibart (INBRX‑109) in unresectable or metastatic chondrosarcoma, meeting the primary endpoint with a statistically significant...
10x, Roche and Prognosys sue Illumina – nine spatial and single‑cell patents at issue
10x Genomics, Roche Sequencing Solutions and Prognosys Biosciences filed twin lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell sequencing...
Deep learning accelerates antibiotic discovery – Nature Biotechnology validates AI‑guided screens
A team published in Nature Biotechnology demonstrated that deep‑learning models trained on high‑throughput phenotypic screening data can identify structurally novel antibacterial scaffolds,...
Detailed LNP structures revealed – path to tissue‑specific RNA delivery
Researchers from the University of Pennsylvania and collaborators published biophysical analyses mapping the architecture of lipid nanoparticles (LNPs), revealing distinct shapes and internal...
Retrons repurposed as a new class of genome editors – scalable, self‑priming DNA donors
Scientists reported repurposing bacterial retrons to produce intracellular single‑stranded DNA donors for gene editing, identifying candidates from metagenomic sequences and validating activity...
Biogen bets on C5aR1: $70m upfront to Vanqua, $990m more possible
Biogen struck an exclusive global licensing deal for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front and agreeing to nearly $1 billion in downstream milestones. The...
Lilly swoops on Adverum: gene therapy buy as cash runs dry
Eli Lilly agreed to acquire Adverum in a deal aimed at securing the biotech’s phase‑3 intravitreal gene therapy ixo‑vec for wet age‑related macular degeneration. Lilly’s offer values Adverum at a...
Two FDA moves on menopause relief: nonhormonal and neurokinin options
The FDA cleared two new therapies for vasomotor symptoms of menopause: elinzanetant, a novel nonhormonal agent, and Bayer’s Lynkuet, described by the company as the first dual neurokinin‑targeted...
Tango’s PRMT5 readout sparks Phase‑3 plan and $225m haul
Tango Therapeutics announced encouraging Phase I/II activity for its MTA‑cooperative PRMT5 inhibitor vopimetostat in MTAP‑deleted pancreatic ductal adenocarcinoma and set a pivotal Phase III start...
Ventyx’s NLRP3 program: swift biomarker cuts ignite buyout chatter
Ventyx Biosciences reported Phase II data showing its oral NLRP3 inhibitor VTX‑3232 produced dramatic reductions in inflammatory biomarkers, including a roughly 78% drop in hsCRP versus placebo,...
Moderna’s CMV setback… and a quieter pivot to oncology
Moderna halted development of its cytomegalovirus vaccine mRNA‑1647 after a Phase III study missed the primary efficacy endpoint, delivering results well below company expectations. The failure...
Deep learning accelerates antibiotic discovery: two Nature Biotech papers
Two complementary Nature Biotechnology reports demonstrate deep‑learning models can markedly speed antibacterial discovery by identifying novel scaffolds and prioritizing hits from phenotypic...
Biophysics peels back LNP structure — design rules for delivery
A multidisciplinary team published detailed biophysical analyses linking lipid nanoparticle (LNP) architecture to delivery performance, illustrating that particle shape and internal structure...
Retrons join the gene‑editing toolkit: metagenomic discovery to engineering
Researchers screened metagenomic datasets and identified retron reverse transcriptases that generate intracellular single‑stranded DNA, then validated and engineered those elements as programmable...
Live embryo imaging upends assumptions about preimplantation aneuploidy
Teams using light‑sheet live imaging tracked late‑stage human preimplantation embryos and found de novo mitotic chromosome segregation errors in cells destined for the trophectoderm, raising...
Lilly buys Adverum — scoops up cash‑strapped gene therapy leader
Eli Lilly agreed to acquire Adverum in a deal that transfers ownership of the biotech’s phase‑3 AAV gene therapy candidate for wet age‑related macular degeneration (ixo‑vec) to the Indianapolis...
FDA returns Blenrep: limited approval with Velcade combo
The U.S. Food and Drug Administration cleared GSK’s antibody‑drug conjugate Blenrep for use in multiple myeloma in a restricted setting, approving the drug only in combination with a Velcade‑based...
Moderna’s CMV vaccine fails Phase 3 — program largely halted
Moderna reported that its mRNA cytomegalovirus vaccine missed primary efficacy endpoints in a pivotal Phase III trial and will stop most development of the candidate. The failure removes what had...
AI finds antibiotics: deep learning surfaces novel antibacterial scaffolds
Two complementary reports in Nature Biotechnology describe how deep‑learning models trained on high‑throughput screening and phenotypic data accelerated discovery of novel antibacterial compounds....
LNP blueprints emerge — biophysics maps nanoparticle diversity
Teams from UPenn, Brookhaven and commercial partners published biophysical analyses that resolve structural heterogeneity across lipid nanoparticle (LNP) formulations used for RNA delivery. The...